De-escalation for HPV
This session will examine the current state of evidence surrounding de-escalation of treatment in patients HPV-associated oropharyngeal cancer. Interdisciplinary experts will discuss key strategies for toxicity mitigation using minimally invasive surgery, radiation dose or volume reduction, and/or systemic therapies.
This meeting is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists, speech language pathologists/scientists, dentists, oral surgeons, swallowing and speech therapists, audiologists, physical therapists, scientists, immunologist and rehabilitation specialists.
Upon completion of this activity, participants should be able to do the following:
- Describe state of science and practice implications for de-escalation of HPV-OPC treatment via surgery.
- Describe state of science and practice implications for de-escalation of HPV-OPC treatment via radiation therapy.
- Describe state of science and practice implications for de-escalation of HPV-OPC treatment via systemic therapy.
Katherine Hutcheson, PhD is employed by MD Anderson Cancer Center and receives research grants from Atos Medical, MD Anderson Institutional Research Grant Program, National Institutes of Health, Patient Centered Outcomes Research Institute and THRIVE/HESI Foundation.
Umamaheswar Duvvuri, MD, PhD is employed by the University of Pittsburgh and is a consultant with Activ Surgical.
Bhisham Chera, MD is employed by the UNC School of Medicine and has stock in Naveris and also holds leadership positions with the ACR, Navaris and Practical Radiation Oncology.
Neil Hayes, MD, the employed by the University of Tennessee Health Science Center and has no financial relationships with a commercial interest.
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.